Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Urinary PSA in monitoring of patients with prostate cancer.

Pejcić T, Dimitrijević V, Hadzi-Djokić J.

Acta Chir Iugosl. 2012;59(1):57-60.

PMID:
22924305
2.

Urinary prostate specific antigen: is the clinical use likely?

Pejcic T, Hadzi-Djokic J, Acimovic M, Topuzovic C, Milkovic B, Janjic A.

Acta Chir Iugosl. 2005;52(4):69-74.

PMID:
16673599
3.

Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?

Pejcic TP, Tulic CDz, Lalic NV, Glisic BD, Ignjatovic SD, Markovic BB, Hadzi-Djokic JB.

Can J Urol. 2013 Apr;20(2):6707-13.

PMID:
23587511
6.

Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.

Stamey TA, Ekman PE, Blankenstein MA, Cooper EH, Kontturi M, Lilja H, Oesterling JE, Stenman UH, Turkes A.

Scand J Urol Nephrol Suppl. 1994;162:73-87; discussion 115-27. Review.

PMID:
7529430
7.

Urinary PSA level and relative tumor volume after prostate biopsy.

Pejcić T, Hadzi-Djokić J, Marković B, Dragićević D, Glisić B, Lalić N, Aćimović M, Dzamić Z, Radosavljevic R.

Acta Chir Iugosl. 2009;56(2):17-21.

PMID:
19780325
8.

Prostate-specific antigen in urine.

Breul J, Pickl U, Hartung R.

Eur Urol. 1994;26(1):18-21.

PMID:
7523129
9.

[The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].

Hirao Y, Ozono S, Kagebayashi Y, Yoshi M, Tani Y, Uemura H, Momose H, Okajima E.

Hinyokika Kiyo. 1996 Oct;42(10):795-804. Japanese.

11.
12.
13.

Cytokine variations in patients with hormone treated prostate cancer.

Wise GJ, Marella VK, Talluri G, Shirazian D.

J Urol. 2000 Sep;164(3 Pt 1):722-5.

PMID:
10953133
14.

Likelihood of prostate cancer based on prostate-specific antigen density by MRI: retrospective analysis.

Mueller-Lisse UG, Mueller-Lisse UL, Haller S, Schneede P, Scheidler JE, Schmeller N, Hofstetter AG, Reiser MF.

J Comput Assist Tomogr. 2002 May-Jun;26(3):432-7.

PMID:
12016375
15.

Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.

Hillenbrand M, Bastian M, Steiner M, Zingler C, Müller M, Wolff JM, Seiter H, Schuff-Werner P.

Anticancer Res. 2000 Nov-Dec;20(6D):4995-6.

PMID:
11326656
17.

Serum-to-urinary prostate-specific antigen ratio: a potential means of distinguishing benign prostatic hyperplasia from prostate cancer.

Irani J, Millet C, Levillain P, Doré B, Begon F, Aubert J.

Eur Urol. 1996;29(4):407-12.

PMID:
8791046
20.

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D; Southwest Oncology Group Trial 9346 (INT-0162)..

J Clin Oncol. 2006 Aug 20;24(24):3984-90.

PMID:
16921051

Supplemental Content

Support Center